A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Humans Glioblastoma / immunology Female Vaccines, Subunit / immunology Cancer Vaccines / immunology Male Middle Aged Precision Medicine / methods Aged Adult Brain Neoplasms / immunology Antigens, Neoplasm / immunology T-Lymphocytes / immunology Treatment Outcome Protein Subunit Vaccines

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
11 Aug 2024

Historique:

received: 29 02 2024

accepted: 06 08 2024

medline: 11 8 2024

pubmed: 11 8 2024

entrez: 10 8 2024

Statut: epublish

Résumé

Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.

Identifiants

DOI: 10.1038/s41467-024-51315-8 PMID: 39127809

pubmed: 39127809

doi: 10.1038/s41467-024-51315-8

pii: 10.1038/s41467-024-51315-8

doi:

Substances chimiques

Vaccines, Subunit 0

Cancer Vaccines 0

Antigens, Neoplasm 0

Protein Subunit Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

6870

Informations de copyright

Références

Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

doi: 10.1056/NEJMoa043330 pubmed: 15758009

Stupp, R. et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).

doi: 10.1016/j.ejca.2012.04.011 pubmed: 22608262

Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314, 2535–2543 (2015).

doi: 10.1001/jama.2015.16669 pubmed: 26670971

Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306–2316 (2017).

doi: 10.1001/jama.2017.18718 pubmed: 29260225 pmcid: 5820703

Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).

doi: 10.1056/NEJMoa1308345 pubmed: 24552318

Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).

doi: 10.1056/NEJMoa1308573 pubmed: 24552317 pmcid: 4201043

Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25, 123–134 (2023).

doi: 10.1093/neuonc/noac099 pubmed: 35419607

Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935–1949 (2022).

doi: 10.1093/neuonc/noac116 pubmed: 35511454 pmcid: 9629431

Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003–1010 (2020).

doi: 10.1001/jamaoncol.2020.1024 pubmed: 32437507

Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

doi: 10.1016/S1470-2045(17)30517-X pubmed: 28844499

Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100–1108 (2014).

doi: 10.1016/S1470-2045(14)70379-1 pubmed: 25163906

Saxena, M. et al. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).

doi: 10.1038/s41568-021-00346-0 pubmed: 33907315

Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770–2788 (2022).

doi: 10.1016/j.cell.2022.06.035 pubmed: 35835100 pmcid: 9555301

Dunn, G. P., Sherpa, N., Manyanga, J. & Johanns, T. M. Considerations for personalized neoantigen vaccination in malignant glioma. Adv. Drug Deliv. Rev. 186, 114312 (2022).

doi: 10.1016/j.addr.2022.114312 pubmed: 35487282

Grassl, N. et al. A H3K27M-targeted vaccine in adults with diffuse midline glioma. Nat. Med. 29, 2586–2592 (2023).

doi: 10.1038/s41591-023-02555-6 pubmed: 37735561 pmcid: 10579055

Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).

doi: 10.1038/s41586-018-0810-y pubmed: 30568303

Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).

doi: 10.1038/s41586-018-0792-9 pubmed: 30568305

Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463–468 (2021).

doi: 10.1038/s41586-021-03363-z pubmed: 33762734 pmcid: 8046668

Lakomy, R. et al. Real-world evidence in glioblastoma: Stupp’s regimen after a decade. Front Oncol. 10, 840 (2020).

doi: 10.3389/fonc.2020.00840 pubmed: 32719739 pmcid: 7348058

Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019).

doi: 10.1038/s41586-019-1775-1 pubmed: 31748746 pmcid: 6897368

Brennan et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).

doi: 10.1016/j.cell.2013.09.034 pubmed: 24120142 pmcid: 3910500

Jonsson, P. et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin. Cancer Res. 25, 5537–5547 (2019).

doi: 10.1158/1078-0432.CCR-19-0032 pubmed: 31263031 pmcid: 6753053

Ho, D. et al. MatchIt: nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1–28 (2011).

doi: 10.18637/jss.v042.i08

Caliendo, M. & Kopeinig, S. Some practical guidance for the implementation of propensity score matching. J. Economic Surv. 22, 31–72 (2008).

doi: 10.1111/j.1467-6419.2007.00527.x

Ho, D. E. et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit. anal. 15, 199–236 (2007).

doi: 10.1093/pan/mpl013

Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).

doi: 10.1038/nm.2883 pubmed: 22842478

WHO Classification of Tumours Editorial Board. Central nervous system tumours. WHO Classification of Tumours Series, 5th edn, Vol. 6 (Lyon (France), International Agency for Research on Cancer, 2021).

Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310–3316 (2014).

doi: 10.1093/bioinformatics/btu548 pubmed: 25143287 pmcid: 4441069

Blumendeller, C. et al. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report. J. Immunother. Cancer 9, e001406 (2021).

doi: 10.1136/jitc-2020-001406 pubmed: 33431630 pmcid: 7802705

Zelba, H. et al. Adjuvant treatment for breast cancer patients using individualized neoantigen peptide vaccination—a retrospective observation. Vaccines 10, 1882 (2022).

doi: 10.3390/vaccines10111882 pubmed: 36366390 pmcid: 9698403

Zelba H., et al. Case report: targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer. Front. Immunol. 14, 1271449 (2023).

Zelba, H. et al. A highly specific assay for the detection of SARS-CoV-2-reactive CD4+ and CD8+ T cells in COVID-19 patients. J. Immunol. 206, 580–587 (2021).

doi: 10.4049/jimmunol.2000811 pubmed: 33298615

Michaelsen, S. R. et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC cancer 13, 402 (2013).

doi: 10.1186/1471-2407-13-402 pubmed: 24004722 pmcid: 3766209

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (2020).

Therneau T. _A Package for Survival Analysis in S_. version 2.38, https://CRAN.R-project.org/package=survival (2015).

T. M. Therneau, P. M. Grambsch. _Modeling Survival Data: Extending the Cox Model_. Springer, New York. ISBN 0-387-98784-3. (2000).

A. Kassambara, M. Kosinski and P. Biecek. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.9. https://CRAN.R-project.org/package=survminer (2021).